EP2269604B1 - Treatment of solid kidney tumours with a rapamycin derivative - Google Patents

Treatment of solid kidney tumours with a rapamycin derivative Download PDF

Info

Publication number
EP2269604B1
EP2269604B1 EP10174985.1A EP10174985A EP2269604B1 EP 2269604 B1 EP2269604 B1 EP 2269604B1 EP 10174985 A EP10174985 A EP 10174985A EP 2269604 B1 EP2269604 B1 EP 2269604B1
Authority
EP
European Patent Office
Prior art keywords
compound
tumor
tumors
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
EP10174985.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2269604A1 (en
Inventor
Heidi Lane
Terence O'reilly
Jeanette Marjorie Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26245731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2269604(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0104072A external-priority patent/GB0104072D0/en
Priority claimed from GB0124957A external-priority patent/GB0124957D0/en
Application filed by Novartis AG filed Critical Novartis AG
Priority to SI200231078A priority Critical patent/SI2269604T1/sl
Publication of EP2269604A1 publication Critical patent/EP2269604A1/en
Application granted granted Critical
Publication of EP2269604B1 publication Critical patent/EP2269604B1/en
Priority to CY20161101060T priority patent/CY1118316T1/el
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Definitions

  • the present invention relates to a new use, in particular a new use for 40-0-(2-hydroxyethyl)-rapamycin.
  • Rapamycin is a known macrolide antibiotic produced by Streptomyces hygroscopicus. Suitable derivatives of rapamycin include e.g. compounds of formula I wherein
  • Compound A More preferable compound 40-0-(2-hydroxyethyl)-rapamycin (referred thereafter as Compound A) was disclosed as Example 8 in WO 94/09010 .
  • Compounds of formula I have, on the basis of observed activity, e.g. binding to macrophilin-12 (also known as FK-506 binding protein or FKBP-12), e.g. as described in WO 94/09010 , WO 95/16691 or WO 96/41807 , been found to be useful e.g. as immunosuppressant, e.g. in the treatment of acute allograft rejection. It has now been found that Compounds of formula I have potent antiproliferative properties which make them useful for cancer chemotherapy, particularly of solid tumors, especially of advanced solid tumors. There is still the need to expand the armamentarium of cancer treatment of solid tumors, especially in cases where treatment with anticancer compounds is not associated with disease regression or stabilization.
  • solid tumors tumors and/or metastasis (whereever located) other than lymphatic cancer, e.g. brain and other central nervous system tumors (eg. tumors of the meninges, brain, spinal cord, cranial nerves and other parts of central nervous system, e.g. glioblastomas or medulla blastomas); head and/or neck cancer; breast tumors; circulatory system tumors (e.g. heart, mediastinum and pleura, and other intrathoracic organs, vascular tumors and tumor-associated vascular tissue); excretory system tumors (e.g. kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs); gastrointestinal tract tumors (e.g.
  • oesophagus oesophagus, stomach, small intestine, colon, colorectal, rectosigmoid junction, rectum, anus and anal canal
  • vulva vagina, Cervix uteri, Corpus uteri, uterus, ovary, and other sites associated with female genital organs, placenta, penis, prostate, testis, and other sites associated with male genital organs); respiratory tract tumors (e.g. nasal cavity and middle ear, accessory sinuses, larynx, trachea, bronchus and lung, e.g. small cell lung cancer or non-small cell lung cancer); skeletal system tumors (e.g. bone and articular cartilage of limbs, bone articular cartilage and other sites); skin tumors (e.g.
  • malignant melanoma of the skin non-melanoma skin cancer, basal cell carcinoma of skin, squamous cell carcinoma of skin, mesothelioma, Kaposi's sarcoma); and tumors involving other tissues incluing peripheral nerves and autonomic nervous system, connective and soft tissue, retroperitoneum and peritoneum, eye and adnexa, thyroid, adrenal gland and other endocrine glands and related structures, secondary and unspecified malignant neoplasm of lymph nodes, secondary malignant neoplasm of respiratory and digestive systems and secondary malignant neoplasm of other sites.
  • a tumor a tumor disease, a carcinoma or a cancer
  • metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis is.
  • diseases associated with deregulated angiogenesis include without limitation e.g. neoplastic diseases, e.g. solid tumors.
  • Angiogenesis is regarded as a prerequisite for those tumors which grow beyond a certain diameter, e.g. about 1-2 mm.
  • lymphatic cancer e.g. tumors of blood and lymphatic system (e.g. Hodgkin's disease, Non-Hodgkin's lymphoma, Burkitt's lymphoma, AIDS-related lymphomas, malignant immunoproliferative diseases, multiple myeloma and malignant plasma cell neoplasms, lymphoid leukemia, myeloid leukemia, acute or chronic lymphocytic leukemia, monocytic leukemia, other leukemias of specified cell type, leukemia of unspecified cell type, other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues, for example diffuse large cell lymphoma, T-cell lymphoma or cutaneous T-cell lymphoma).
  • lymphatic system e.g. Hodgkin's disease, Non-Hodgkin's lymphoma, Burkitt's lymphoma, AIDS-related lymphomas, malignant immuno
  • the subject-matter relating to the compounds comprises likewise the pharmaceutically acceptable salts thereof, the corresponding racemates, diastereoisomers, enantiomers, tautomers as well as the corresponding crystal modifications of above disclosed compounds where present, e.g. solvates, hydrates and polymorphs, which are disclosed therein.
  • the compounds used as active ingredients in the combinations of the disclosure can be prepared and administered as described in the cited documents, respectively.
  • a cell line the Compound A resistant A549 line (IC 50 in low nM range) versus the comparative Compound A resistant KB-31 and HCT116 lines (IC 50 in the ⁇ M range) is added to 96-well plates (1,500 cells/well in 100 ⁇ l medium) and incubated for 24 hr. Subsequently, a two-fold dilution series of each compound (Compound of formula I or a known chemotherapeutic agent) is made in separate tubes (starting at 8 x the IC 50 of each compound) either alone or in paired combinations, and the dilutions are added to the wells. The cells are then re-incubated for 3 days.
  • CI non-exclusive combination index
  • CI ⁇ 1 the interaction is nearly additive
  • 0.85 - 0.9 slight synergism
  • ⁇ 0.85 synergy.
  • the Compound A shows interesting antiproliferative activity in combination with another chemotherapeutic agent.
  • CI values are obtained with a combination of Compound A and cisplatinum, paclitaxel, gemcitabine and doxorubicin, showing synergistic effects.
  • CI Cell line Cisplatinum Paclitaxel Gemcitabine Doxorubicin KB-31 0.74 0.9 0.79 0.7 A549 0.47 0.74 0.76 0.64 HCT116 0.47 0.3 0.9 0.52
  • Compound A potentiates the loss of A549 cell viability and cell death when it is used in combination with gemcitabine.
  • antitumor activity is expressed as T/C% (mean increase in tumor volumes of treated animals divided by the mean increase of tumor volumes of control animals multiplied by 100) and % regressions (tumor volume minus initial tumor volume divided by the initial tumor volume and multiplied by 100).
  • Fragments of A549 tumors (approx. 25 mg; derived from Cell line CCL 185, ATCC, Rockville MD, USA) are transplanted subcutaneously into the left flank of BALB/c nude mice. Treatment is started on day 7 or day 12 following tumor transplantation. The compound to be tested is administered p.o. once per day from day 7/12 to day 38/55, respectively.
  • the compounds of formula I when administered at a daily dose ranging from 0.1 mg/kg to 2.5 mg/kg, the compounds of formula I exhibit dose-dependent inhibition of tumor growth; for example in one representative experiment Compound A when administered at a dose of 2.5 mg/kg results in persisting regressions (41 %); a dose of 0.5 mg/kg results in transient regressions (38 % on day 17), with a final T/C of 16 %, and a dose of 0.1 mg/kg slows tumor growth resulting in a final T/C of 43 % (T/C for control animals is 100%).
  • Fragments of KB-31 tumors (approx. 25 mg; derived from the cell lines obtained from Roswell Park Memorial Institute Buffalo, NY, USA) are transplanted subcutaneously into the left flank of BALB/c nude mice. Treatment is started on day 7 or on day 10 following tumor transplantation. The compound to be tested is administered p.o. once per day from day 7/10 to day 25/35, respectively. Antitumor activity is expressed as T/C% as indicated above.
  • the compounds of formula I when administered at a daily dose ranging from 0.5 mg/kg to 2.5 mg/kg, the compounds of formula I inhibit tumor growth; for example in one representative experiment Compound A when administered at a dose of 2,5 mg/kg/day results in a final T/C cvalue of 25%(T/C for control animals is 100%).
  • Tumors are established in male Lewis rats by subcutaneous injection of CA20948 tumor cell suspension derived from donor rats into the left flank. Treatment is started on day 4 post inoculation.
  • the compound to be tested is administered p.o. once per day (6 days a week) from day 4 to day 9-15 post inoculation.
  • Antitumor activity is expressed as T/C% as indicated above.
  • the compounds of formula I when administered at a daily dose of 0.5 mg/kg to 2.5 mg/kg, the compounds of formula I inhibit tumor growth; for example in a representative experiment Compound A when administered p.o. at a daily dose of 2.5 mg/kg results in a final T/C value of 23 %.
  • Compound A has been tested in further tumor models in accordance with the procedure as disclosed above. For example, a daily dosage of 2.5 mg/kg or 5 mg/kg Compound A produces final T/Cs of 18% and 9% when administered to the human NCI H-596 lung tumor model and the human MEXF 989 melanoma tumor model, respectively; 5 mg/kg produces final T/Cs of 20% (primary tumor) and 36% (cervical lymph node metastases) when administered to the orthotopic mouse B16/BL6 melanoma tumor model and 24% when administered to the human AR42J pancreatic tumor model; 2.5 mg/kg produces a final T/C of 28% when administered to the multi-drug resistant (MDR) human KB-8511 epidermoid tumor model. Good antitumor responses are also obtained when Compound A is administered intermittently, e.g. 2 subsequent days per week or twice a week, to mice transplanted with human AR42J pancreatic tumors.
  • MDR multi-drug resistant
  • mice transplanted with human KB-31 epidermoid tumors are treated for 21 days with doxorubicin at a dose of 5 mg/kg i.v. once per week, Compound A at a dose of 2.5 mg/kg p.o once per day, or a combination of both. Thereafter Compound A treatment alone is continued in the combination group in order to determine if the Compound A can suppress the outgrowth of tumors that respond to conventional agents.
  • Antitumor activity is expressed as T/C% or % regressions as indicated above.
  • the combination of Compound A and doxorubicin produces greater antitumor effect (74 % regressions) as compared to either agent alone (Compound A, T/C 32 %; doxorubicin 44 % regressions).
  • No exacerbation of the body weight losses caused by doxorubicin occurs when Compound A treatment is added.
  • Compound A treatment in the combination group after ceasing doxorubicin, inhibits tumor outgrowth such that the tumor volumes of the doxorubicin monotherapy group are significantly larger than those of the combination group.
  • the combination appears to produce a greater cure rate (8/8 tumors) at 14 days post end of treatment than doxorubicin alone (3/8 tumors).
  • mice transplanted with human NCI H-596 lung tumors are treated for 21 days with cisplatinum at a dose of 2.5 mg/kg i.v. once per week, Compound A, at a dose of 2.5 mg/kg p.o. once per day, or a combination of both.
  • Antitumor activity is expressed as T/C% or % regressions as indicated above.
  • a combination of Compound A and cisplatinum produces a greater antitumor effect (5% regressions) as compared to either agent alone (Compound A, T/C 26%; cisplatinum, T/C 26%). The combination did not lead to worsened tolerability.
  • B16/BL6 cells (5 X10 4 ) are injected intradermally into the ear of C57BL/6 mice. Seven days later treatment with Compound A or vehicle is initiated. Primary tumor and cervical lymph nodes are collected after two weeks of daily treatment for measurement of vessel density. Endothelium of perfused vessels in the tumors is visualized using a nuclear staining dye (Hoechst 33342, 20 mg/kg) that is injected i.v. shortly before killing the mice. Tumors and metastases are snap frozen and sections examined under a light microscope equipped with an epifluorescent source. The fluorescence H33342-labelled endothelium cells are used to measure vessel number and size over the whole tumor section. Vessels are assigned to groups of 10 ⁇ m-size range.
  • Compound A reduces vessel density in both the primary tumor (e.g. T/C 50 % for Compound A) and the metastases (e.g.T/C 40 % for Compound A) as compared to controls. Compound A also changes vessel size distribution in the metastases.
  • B16/BL6 cells (5 X10 4 ) are injected intradermally into the ear of C57BL/6 mice. Seven days later treatment with Compound A, a VEGF receptor tyrosine kinase inhibitor, e.g. 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a salt thereof, e.g. the succinate, or a combination of both is initiated and effects on the growth and weight of the primary tumor and cervical lymph node metastases are monitored, respectively.
  • a VEGF receptor tyrosine kinase inhibitor e.g. 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a salt thereof, e.g. the succinate, or a combination of both is initiated and effects on the growth and weight of the primary tumor and cervical lymph node metastases are monitored, respectively.
  • Suitable clinical studies are, for example, open label non-randomized, dose escalation studies in patients with advanced solid tumors. Such studies prove in particular the synergism of the active ingredients of the combination.
  • the beneficial effects on proliferative diseases can be determined directly through the results of these studies or by changes in the study design which are known as such to a person skilled in the art.
  • Such studies are, in particular, suitable to compare the effects of a monotherapy using the active ingredients and a combination of the disclosure.
  • the dose of agent (a) is escalated until the Maximum Tolerated Dosage is reached, and the co-agent (b) is administered with a fixed dose.
  • the agent (a) is administered in a fixed dose and the dose of co-agent (b) is escalated.
  • Each patient receives doses of the agent (a) either daily or intermittent.
  • the efficacy of the treatment can be determined in such studies, e.g., after 12, 18 or 24 weeks by radiologic evaluation of the tumors every 6 weeks.
  • Daily dosages required in practicing the method of the present invention when a compound of formula I alone is used will vary depending upon, for example, the compound used, the host, the mode of administration and the severity of the condition to be treated.
  • a preferred daily dosage range is about from 0.1 to 25 mg as a single dose or in divided doses.
  • Suitable daily dosages for patients are on the order of from e.g. 0.1 to 25 mg p.o.
  • Compound A may be administered by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets, capsules, drink solutions, nasally, pulmonary (by inhalation) or parenterally, e.g. in the form of injectable solutions or suspensions.
  • Suitable unit dosage forms for oral administration comprise from ca. 0.05 to 12.5 mg, usually 0.25 to 10 mg Compound A, together with one or more pharmaceutically acceptable diluents or carriers therefor.
  • a pharmaceutical combination of the disclosure results not only in a beneficial effect, e.g. a synergistic therapeutic effect, e.g. with regard to slowing down, arresting or reversing the neoplasm formation or a longer duration of tumor response, but also in further surprising beneficial effects, e.g. less side-effects, an improved quality of life or a decreased mortality and morbidity, compared to a monotherapy applying only one of the pharmaceutically active ingredients used in the combination of the disclosure, in particular in the treatment of a tumor that is refractory to other chemotherapeutics known as anti-cancer agents.
  • Suitable pharmaceutical compositions contain, for example, from about 0.1 % to about 99.9%, preferably from about 1 % to about 60 %, of the active ingredient.
  • Pharmaceutical preparations for the combination therapy for enteral or parenteral administration are, for example, those in unit dosage forms, such as sugar-coated tablets, tablets, capsules or suppositories, or ampoules. If not indicated otherwise, these are prepared in a manner known per se, for example by means of conventional mixing, granulating, sugar-coating, dissolving or lyophilizing processes. It will be appreciated that the unit content of a combination partner contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount can be reached by administration of a plurality of dosage units.
  • a therapeutically effective amount of each of the combination partner of the combination disclosed herein may be administered simultaneously or sequentially and in any order, and the components may be administered separately or as a fixed combination.
  • the method of delay of progression or treatment of a proliferative malignant disease according to the disclosure may comprise (i) administration of the first agent a) in free or pharmaceutically acceptable salt form and (ii) administration of a co-agent b) in free or pharmaceutically acceptable salt form, simultaneously or sequentially in any order, in jointly therapeutically effective amounts, preferably in synergistically effective amounts, e.g. in daily or intermittently dosages corresponding to the amounts described herein.
  • the individual combination partners of the combination disclosed herein may be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
  • administering also encompasses the use of a pro-drug of a combination partner that convert in vivo to the combination partner as such.
  • each of the combination partners employed in the combination disclosed herein may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the condition being treated, the severity of the condition being treated.
  • the dosage regimen of the combination disclosed herein is selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient.
  • a physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the single active ingredients required to prevent, counter or arrest the progress of the condition.
  • Optimal precision in achieving concentration of the active ingredients within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the active ingredients' availability to target sites.
  • Rapamycin or a derivative thereof e.g. a compound of formula I
  • Suitable unit dosage forms for oral administration comprise from ca. 0.05 to 10 mg active ingredient, e.g. Compound A, together with one or more pharmaceutically acceptable diluents or carriers therefor.
  • Compound A is well tolerated at dosages required for use in accordance with the present invention.
  • the NTEL for Compound A in a 4-week toxicity study is 0.5 mg/kg/day in rats and 1.5 mg/kg/day in monkeys.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
EP10174985.1A 2001-02-19 2002-02-18 Treatment of solid kidney tumours with a rapamycin derivative Revoked EP2269604B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI200231078A SI2269604T1 (sl) 2001-02-19 2002-02-18 Zdravljenje solidnih tumorjev ledvic z rapamicinskim derivatom
CY20161101060T CY1118316T1 (el) 2001-02-19 2016-10-21 Θεραπεια συμπαγων νεφρικων ογκων με ενα παραγωγο ραπαμυκινης

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0104072A GB0104072D0 (en) 2001-02-19 2001-02-19 Organic compounds
GB0124957A GB0124957D0 (en) 2001-10-17 2001-10-17 Organic compounds
EP02719864A EP1363627A2 (en) 2001-02-19 2002-02-18 Treatment of solid tumours with rapamycin derivatives

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP02719864.7 Division 2002-02-18
EP02719864A Division EP1363627A2 (en) 2001-02-19 2002-02-18 Treatment of solid tumours with rapamycin derivatives

Publications (2)

Publication Number Publication Date
EP2269604A1 EP2269604A1 (en) 2011-01-05
EP2269604B1 true EP2269604B1 (en) 2016-07-27

Family

ID=26245731

Family Applications (11)

Application Number Title Priority Date Filing Date
EP10174985.1A Revoked EP2269604B1 (en) 2001-02-19 2002-02-18 Treatment of solid kidney tumours with a rapamycin derivative
EP14164565.5A Revoked EP2762140B1 (en) 2001-02-19 2002-02-18 Treatment of solid brain tumours with a rapamycin derivative
EP16186041.6A Expired - Lifetime EP3143995B2 (en) 2001-02-19 2002-02-18 Rapamycin derivative for the treatment of lung cancer
EP18155644.0A Revoked EP3351246B8 (en) 2001-02-19 2002-02-18 Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis
EP18155724.0A Expired - Lifetime EP3342411B1 (en) 2001-02-19 2002-02-18 Rapamycin derivative for treating pancreas cancer
EP02719864A Withdrawn EP1363627A2 (en) 2001-02-19 2002-02-18 Treatment of solid tumours with rapamycin derivatives
EP14164259.5A Revoked EP2783686B1 (en) 2001-02-19 2002-02-18 Combination of a rapamycin derivative and letrozole for treating breast cancer
EP18155722.4A Expired - Lifetime EP3345602B1 (en) 2001-02-19 2002-02-18 Rapamycin derivative for treating solid tumours
EP20100174983 Revoked EP2269603B1 (en) 2001-02-19 2002-02-18 Treatment of breast tumors with a rapamycin derivative in combination with exemestane
EP18181342.9A Withdrawn EP3406249A1 (en) 2001-02-19 2002-02-18 Treatment of breast tumors with a rapamycin derivative in combination with an aromatase inhibitor
EP14164561.4A Withdrawn EP2764865A3 (en) 2001-02-19 2002-02-18 Cancer treatment

Family Applications After (10)

Application Number Title Priority Date Filing Date
EP14164565.5A Revoked EP2762140B1 (en) 2001-02-19 2002-02-18 Treatment of solid brain tumours with a rapamycin derivative
EP16186041.6A Expired - Lifetime EP3143995B2 (en) 2001-02-19 2002-02-18 Rapamycin derivative for the treatment of lung cancer
EP18155644.0A Revoked EP3351246B8 (en) 2001-02-19 2002-02-18 Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis
EP18155724.0A Expired - Lifetime EP3342411B1 (en) 2001-02-19 2002-02-18 Rapamycin derivative for treating pancreas cancer
EP02719864A Withdrawn EP1363627A2 (en) 2001-02-19 2002-02-18 Treatment of solid tumours with rapamycin derivatives
EP14164259.5A Revoked EP2783686B1 (en) 2001-02-19 2002-02-18 Combination of a rapamycin derivative and letrozole for treating breast cancer
EP18155722.4A Expired - Lifetime EP3345602B1 (en) 2001-02-19 2002-02-18 Rapamycin derivative for treating solid tumours
EP20100174983 Revoked EP2269603B1 (en) 2001-02-19 2002-02-18 Treatment of breast tumors with a rapamycin derivative in combination with exemestane
EP18181342.9A Withdrawn EP3406249A1 (en) 2001-02-19 2002-02-18 Treatment of breast tumors with a rapamycin derivative in combination with an aromatase inhibitor
EP14164561.4A Withdrawn EP2764865A3 (en) 2001-02-19 2002-02-18 Cancer treatment

Country Status (27)

Country Link
US (10) US8410131B2 (OSRAM)
EP (11) EP2269604B1 (OSRAM)
JP (14) JP2004525899A (OSRAM)
KR (3) KR100695846B1 (OSRAM)
CN (5) CN1551767A (OSRAM)
AU (1) AU2002250968C1 (OSRAM)
BR (1) BR0207378A (OSRAM)
CA (3) CA2438504C (OSRAM)
CY (11) CY1116616T1 (OSRAM)
CZ (5) CZ307940B6 (OSRAM)
DK (6) DK3143995T3 (OSRAM)
ES (8) ES2640787T3 (OSRAM)
HK (2) HK1250336B (OSRAM)
HU (1) HUP0303271A3 (OSRAM)
IL (13) IL157425A0 (OSRAM)
LT (9) LT2762140T (OSRAM)
LU (3) LU92880I2 (OSRAM)
MX (3) MXPA03007418A (OSRAM)
NO (14) NO333105B1 (OSRAM)
NZ (1) NZ527692A (OSRAM)
PL (5) PL231418B1 (OSRAM)
PT (7) PT2269603E (OSRAM)
RU (8) RU2322981C2 (OSRAM)
SI (6) SI3342411T1 (OSRAM)
SK (5) SK288834B6 (OSRAM)
TW (2) TW200626151A (OSRAM)
WO (1) WO2002066019A2 (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
ES2640787T3 (es) 2001-02-19 2017-11-06 Novartis Ag Combinación de un derivado de rapamicina y letrozol para tratar el cáncer de mama
NZ529877A (en) * 2001-06-01 2006-08-31 Wyeth Corp Antineoplastic combinations
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
EP1545553B1 (de) 2002-07-30 2011-07-13 Æterna Zentaris GmbH Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
US7846141B2 (en) 2002-09-03 2010-12-07 Bluesky Medical Group Incorporated Reduced pressure treatment system
US20060094766A1 (en) * 2002-10-11 2006-05-04 Boris Lin Epothilone derivatives for the treatment of multiple myeloma
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US20070020704A1 (en) 2003-05-20 2007-01-25 Scott Wilhelm Diaryl ureas with kinase inhibiting activity
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
MXPA06009550A (es) * 2004-02-23 2007-03-01 Novartis Ag P53 tipo natural como biomarcadores para el tratamiento con inhibidores de mtor en combinacion con un agente citotoxico.
US20080113039A1 (en) * 2004-03-23 2008-05-15 Stephen Robert Wedge Combination Therapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
EP2388315B1 (en) * 2005-03-07 2014-05-21 The University of Western Ontario Use of a Myxoma virus that does not express functional M135R for therapeutic treatment
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
EP1909794A2 (en) * 2005-07-20 2008-04-16 Novartis AG Combination of organic compounds
EP1962839A4 (en) 2005-11-14 2010-08-25 Ariad Pharma Inc ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
PT2275103E (pt) * 2005-11-21 2014-07-24 Novartis Ag Inibidores de mtor para o tratamento de tumores endócrinos
KR20140016439A (ko) 2006-02-02 2014-02-07 노파르티스 아게 결절성 경화증의 치료
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
CN101415409B (zh) * 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
US20080085874A1 (en) * 2006-08-28 2008-04-10 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
US9820888B2 (en) 2006-09-26 2017-11-21 Smith & Nephew, Inc. Wound dressing
ES2690174T3 (es) * 2007-03-07 2018-11-19 Abraxis Bioscience, Llc Nanopartícula que comprende rapamicina y albúmina como agente antineoplásico
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101292980B (zh) * 2007-04-28 2010-11-10 上海交通大学医学院附属仁济医院 一种含有雷帕霉素的用于治疗大肠癌的药物组合物
US20110229572A1 (en) * 2007-08-16 2011-09-22 Biocompatibles Uk Limited Delivery of drug combinations
WO2009058895A1 (en) * 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
US8298200B2 (en) 2009-06-01 2012-10-30 Tyco Healthcare Group Lp System for providing continual drainage in negative pressure wound therapy
US20120040896A1 (en) * 2008-04-11 2012-02-16 The Regents Of The University Of Colorado Compositions, methods and uses for modulation of brca 1
RU2509774C2 (ru) * 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
GB0902368D0 (en) 2009-02-13 2009-04-01 Smith & Nephew Wound packing
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
US8791315B2 (en) 2010-02-26 2014-07-29 Smith & Nephew, Inc. Systems and methods for using negative pressure wound therapy to manage open abdominal wounds
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.
DK2606070T3 (en) 2010-08-20 2017-03-27 Novartis Ag Antibodies for the epidermal growth factor receptor 3 (HER3)
JP6243345B2 (ja) * 2011-12-05 2017-12-06 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
CN107049603B (zh) 2012-05-23 2021-01-26 史密夫及内修公开有限公司 用于负压伤口治疗的装置和方法
BR112015002154A2 (pt) 2012-08-01 2017-07-04 Smith & Nephew curativo de ferimento
MX2015001520A (es) 2012-08-01 2015-08-20 Smith & Nephew Apósito para heridas.
AU2014229777B2 (en) 2013-03-15 2018-03-08 Smith & Nephew Plc Wound dressing and method of treatment
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
JP6623745B2 (ja) * 2015-06-29 2019-12-25 富士通株式会社 電子回路及び発振器の制御方法
NZ736853A (en) * 2015-08-17 2019-09-27 Kura Oncology Inc Methods of treating cancer patients with farnesyl transferase inhibitors
CA3016446A1 (en) * 2016-03-15 2017-09-21 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer
US20200081010A1 (en) 2016-12-02 2020-03-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for diagnosing renal cell carcinoma
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019002085A1 (en) 2017-06-30 2019-01-03 Smith & Nephew Plc NEGATIVE PRESSURE WOUND TREATMENT APPARATUS
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
WO2019089556A1 (en) * 2017-10-31 2019-05-09 Steve Gorlin Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
RS64272B1 (sr) 2018-05-01 2023-07-31 Revolution Medicines Inc C40-, c28- i c-32-vezani analozi rapamicina kao inhibitori mtor
CN108825638A (zh) * 2018-08-01 2018-11-16 安徽送变电工程有限公司 一种应用于螺纹工件的防盗装置
WO2020128861A1 (en) 2018-12-18 2020-06-25 Novartis Ag Rapamycin derivatives
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
KR20230053539A (ko) 2021-10-14 2023-04-21 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물
CA3256390A1 (en) 2022-05-25 2023-11-30 Revolution Medicines, Inc. CANCER TREATMENT METHODS USING AN MTOR INHIBITOR

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB104072A (en) 1916-04-14 1917-02-22 William Henry Nosworthy Apparatus for Lighting Fires or Heating or other purposes.
GB124957A (en) 1918-06-04 1919-04-10 Frederick William Miller Improvement in Glass Moulding.
US5066493A (en) 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
WO1993016189A1 (en) * 1992-02-17 1993-08-19 Pfizer Inc. Novel macrocyclic lactones and a productive strain thereof
WO1994009010A1 (en) 1992-10-09 1994-04-28 Sandoz Ltd. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
WO1995016691A1 (en) 1993-12-17 1995-06-22 Sandoz Ltd. Rapamycin derivatives useful as immunosuppressants
WO1996013273A1 (en) 1994-10-26 1996-05-09 Novartis Ag Pharmaceutical compositions
WO1996041807A1 (en) 1995-06-09 1996-12-27 Novartis Ag Rapamycin derivatives
WO1997047317A1 (en) 1996-06-11 1997-12-18 Novartis Ag Combination of a somatostatin analogue and a rapamycin
WO1998011908A1 (en) 1996-09-20 1998-03-26 British Biotech Pharmaceuticals Limited Combination therapy for treatment of arthritic diseases
EP1074255A1 (en) * 1998-04-27 2001-02-07 Fujisawa Pharmaceutical Co., Ltd. Medicinal compositions
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
EP1074263A2 (en) 1995-11-29 2001-02-07 Novartis AG Pharmaceutical compositions of macrolides or cyclosporine with a polyethoylate saturated hydroxy-fatty acid
WO2001051049A1 (en) * 2000-01-14 2001-07-19 The Trustees Of The University Of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
WO2001087372A1 (en) 2000-05-12 2001-11-22 Cordis Corporation Drug combinations useful for prevention of restenosis
WO2002013802A2 (en) 2000-08-11 2002-02-21 Wyeth Method of treating estrogen receptor positive carcinoma
WO2002066019A2 (en) 2001-02-19 2002-08-29 Novartis Ag Cancer treatment
WO2002080975A1 (en) * 2001-04-06 2002-10-17 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
WO2002098416A2 (en) * 2001-06-01 2002-12-12 Wyeth Antineoplastic combinations

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US876165A (en) 1904-05-11 1908-01-07 George K Woodworth Wireless telegraph transmitting system.
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (OSRAM) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
WO1994009019A1 (en) 1992-10-14 1994-04-28 Unichema Chemie B.V. Process for the preparation of alkylglycosides
ATE399181T1 (de) 1992-10-28 2008-07-15 Genentech Inc Verwendung von antagonisten des zellwachstumsfaktors vegf
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
DE4301781C2 (de) 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
WO1995014023A1 (en) 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
GB9325400D0 (en) 1993-12-11 1994-02-16 Sarll David P G Temperature recorder
WO1995028156A1 (en) * 1994-04-14 1995-10-26 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
NZ312665A (en) 1995-07-06 1999-08-30 Novartis Ag Rrolopyrimidines(7h-pyrrolo[2,3-d]pyrimidine and preparation of these
US5567831A (en) * 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
CN1145614C (zh) 1996-04-12 2004-04-14 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂，其制药用途及药物组合物
ES2249800T3 (es) 1996-06-24 2006-04-01 Pfizer Inc. Derivados triciclicos sustituidos con fenilamino para el tratamento de enfermedades hiperproliferativas.
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
AU4176897A (en) 1996-09-09 1998-03-26 American Home Products Corporation Alkylated rapamycin derivatives
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US5985325A (en) 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6152347A (en) 1998-01-30 2000-11-28 Acco Brands, Inc. Vertical Stapler
EP1421939B9 (en) † 1998-03-26 2011-03-02 Astellas Pharma Inc. Sustained release preparation of a macrolide compound like tacrolimus
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1165085E (pt) 1999-03-30 2006-10-31 Novartis Ag Derivados de ftalazina para tratar doencas inflamatorias
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
GB9911582D0 (en) 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
DK1210350T3 (da) 1999-08-18 2004-11-01 Wyeth Corp Vandoplöselige SDZ-RAD-estere
WO2001045740A2 (en) 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions and methods for treatment of breast cancer
US6899731B2 (en) 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
US6641811B1 (en) * 2000-02-10 2003-11-04 Cornell Research Foundation, Inc. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
GB0005257D0 (en) 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020013335A1 (en) 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
AU2001287157A1 (en) * 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
WO2002028387A1 (en) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
ATE367836T1 (de) 2000-10-31 2007-08-15 Cook Inc Beschichtete, implantierbare medizinische geräte
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
DE60130032D1 (de) * 2000-12-22 2007-09-27 Avantec Vascular Corp Vorrichtung zur Abgabe von therapeutischen Wirkstoffen
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7488313B2 (en) 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
JP2003330447A (ja) 2002-05-15 2003-11-19 Mitsubishi Electric Corp 画像処理装置
PT2275103E (pt) 2005-11-21 2014-07-24 Novartis Ag Inibidores de mtor para o tratamento de tumores endócrinos
EP2726140B1 (en) 2011-07-01 2020-12-16 Coloplast A/S A catheter with a balloon
EP2606816A1 (en) 2011-12-22 2013-06-26 Koninklijke Philips Electronics N.V. A method and system for providing an indication as to the amount of milk remaining in a breast during lactation

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB104072A (en) 1916-04-14 1917-02-22 William Henry Nosworthy Apparatus for Lighting Fires or Heating or other purposes.
GB124957A (en) 1918-06-04 1919-04-10 Frederick William Miller Improvement in Glass Moulding.
US5066493A (en) 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
WO1993016189A1 (en) * 1992-02-17 1993-08-19 Pfizer Inc. Novel macrocyclic lactones and a productive strain thereof
WO1994009010A1 (en) 1992-10-09 1994-04-28 Sandoz Ltd. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
US5665772A (en) 1992-10-09 1997-09-09 Sandoz Ltd. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
WO1995016691A1 (en) 1993-12-17 1995-06-22 Sandoz Ltd. Rapamycin derivatives useful as immunosuppressants
WO1996013273A1 (en) 1994-10-26 1996-05-09 Novartis Ag Pharmaceutical compositions
WO1996041807A1 (en) 1995-06-09 1996-12-27 Novartis Ag Rapamycin derivatives
EP1074263A2 (en) 1995-11-29 2001-02-07 Novartis AG Pharmaceutical compositions of macrolides or cyclosporine with a polyethoylate saturated hydroxy-fatty acid
WO1997047317A1 (en) 1996-06-11 1997-12-18 Novartis Ag Combination of a somatostatin analogue and a rapamycin
WO1998011908A1 (en) 1996-09-20 1998-03-26 British Biotech Pharmaceuticals Limited Combination therapy for treatment of arthritic diseases
EP1074255A1 (en) * 1998-04-27 2001-02-07 Fujisawa Pharmaceutical Co., Ltd. Medicinal compositions
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
WO2001051049A1 (en) * 2000-01-14 2001-07-19 The Trustees Of The University Of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
WO2001087372A1 (en) 2000-05-12 2001-11-22 Cordis Corporation Drug combinations useful for prevention of restenosis
WO2002013802A2 (en) 2000-08-11 2002-02-21 Wyeth Method of treating estrogen receptor positive carcinoma
WO2002066019A2 (en) 2001-02-19 2002-08-29 Novartis Ag Cancer treatment
EP2269604A1 (en) 2001-02-19 2011-01-05 Novartis AG Treatment of solid tumours with rapamycin derivatives
WO2002080975A1 (en) * 2001-04-06 2002-10-17 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
WO2002098416A2 (en) * 2001-06-01 2002-12-12 Wyeth Antineoplastic combinations

Non-Patent Citations (43)

* Cited by examiner, † Cited by third party
Title
"Kidney Cancer (Adult) - Renal Cell Carcinoma", AMERICAN CANCER SOCIETY, 16 May 2016 (2016-05-16), pages 1 - 53, XP055376613
"Kidney cancer", WIKIPEDIA, THE FREE ENCYCLOPEDIA, 30 March 2017 (2017-03-30), pages 1 - 6, XP055376543, Retrieved from the Internet <URL:https://en.wikipedia.org/wiki/Kidney_cancer>
"Kidney Tumour", WIKIPEDIA, THE FREE ENCYCLOPEDIA, 18 February 2016 (2016-02-18), XP055260551, Retrieved from the Internet <URL:https://en.wikipedia.org/wiki/Kidney_tumour>
"Kidney tumour", WIKIPEDIA, XP055422897, Retrieved from the Internet <URL:https://en.wikipedia.org/wiki/Kidney_tumour>
"Renal Cell Carcinoma (RCC) , Cornell Urology", WEILL CORNELL MEDICAL COLLEGE, 18 February 2016 (2016-02-18), pages 1 - 6, XP055260557
"Renal Cell Carcinoma (RCC)", CORNELL UROLOGY, 18 February 2016 (2016-02-18), XP055422910, Retrieved from the Internet <URL:www.cornellurology.com/clinical-conditions/kidney-cancer/renal-cell-carcinoma/>
"Renal Cell Carcinoma (RCC)", WEILL CORNELL MEDICAL COLLEGE, 18 February 2016 (2016-02-18), pages 1 - 6, XP055260557
"Renal cell carcinoma", WIKIPEDIA, THE FREE ENCYCLOPEDIA, 30 March 2017 (2017-03-30), pages 1 - 13, XP055376539, Retrieved from the Internet <URL:https://en.wikipedia.org/wiki/Renal_cell_carcinoma>
BEUVINK I ET AL.: "Antitumor activity of RAD001, an orally active rapamycin derivative.", PROC AM ASSOC CANCER RES, vol. 42, 24 March 2001 (2001-03-24), pages 366, XP001093826
GEORGE, S. ET AL.: "Role of everolimus in the treatment of renal cellcarcinoma", THERAPEUTICS AND CLINICAL RISK MANAGEMENT, vol. 5, 2009, pages 699 - 706, XP055376601
GUBA, M ET AL.: "Rapamycin inhibiert das Tumorwachstum und die Tumormetastasierung fiber Antiangiogenese", CHIRURG. FORUM, vol. 30, 2001, pages 37 - 39, XP055422819
GUBA, M. ET AL.: "Rapamycin inhibits tumor growth and metastasis by antiaglogenesis", CHIRURGLSCHES FORUM FUER EXPERIMENTELLE UND KLINISCHE FORSCHUNG, 1 January 2001 (2001-01-01), pages 37 - 39, XP001088707
GUBA, M. ET AL.: "Rapamycin inhibits tumor growth and metastasis by antiangiogenesis", CHIRURGISCHES FORUM FUER EXPERIMENTELLE UND KLINISCHE FORSCHUNG, 1 January 2001 (2001-01-01), pages 37 - 39, XP001088707
HIDALGO M ET AL: "THE RAPAMYCIN-SENSITIVE SIGNAL TRANSDUCTION PATHWAY AS A TARGET FOR CANCER THERAPY", ONCO, vol. 19, no. 56, 2001, pages 6680 - 6686, XP009002368
HIDALGO, M. ET AL.: "Abtract 726 CCI-779, a Rapamycin Analog and Multifaceted Inhibitor Of Signal Transduction: a Phase I Study.", THIRTY-SIXTH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 19, 2000, New Orleans, LA, pages 187a, XP009193117
HIDALGO: "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", ONCOGENE, vol. 19, no. 56, January 2001 (2001-01-01), pages 6680 - 6686, XP009002368
M. HIDALGO ET AL.: "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", ONCOGENE, vol. 19, no. 56, 27 December 2000 (2000-12-27), pages 6680 - 6686, XP009002368
MAJEWSKI M ET AL.: "THE IMMUNOSUPPRESSIVE MACROLIDE RAD INHIBITS GROWTH OF HUMAN EPSTEIN-BARR VIRUS-TRANSFORMED B LYMPHOCYTES IN VITRO AND IN VIVO: A POTENTIAL APPROACH TO PREVENTION AND TREATMENT OF POSTTRANSPLANT LYMPHOPHOUFERATIVE DISORDERS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 97, no. 8, 11 April 2000 (2000-04-11), US, pages 4285 - 4290, XP001093644, ISSN: 0027-8424
MAJEWSKI M ET AL.: "THE IMMUNOSUPPRESSIVE MACROLIDE RAD INHIBITS GROWTH OF HUMAN EPSTEIN-BARR VIRUS-TRANSFORMED B LYMPHOCYTES IN VITRO AND IN VIVO: A POTENTIAL APPROACH TO PREVENTION AND TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 97, no. 8, 11 April 2000 (2000-04-11), US, pages 4285 - 4290, XP001093844, ISSN: 0027-8424
MAJEWSKI M ET AL: "THE IMMUNOSUPPRESSIVE MACROLIDE RAD INHIBITS GROWTH OF HUMAN EPSTEIN-BARR VIRUS-TRANSFORMED B LYMPHOCYTES IN VITRO AND IN VIVO: A POTENTIAL APPROACH TO PREVENTION AND TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 97, no. 8, 11 April 2000 (2000-04-11), pages 4285 - 4290, XP001093844, ISSN: 0027-8424, DOI: 10.1073/PNAS.080068597 *
MAJEWSKI, M. ET AL.: "THE IMMUNOSUPPRESSIVE MACROLIDE RAD INHIBITS GROWTH OF HUMAN EPSTEIN-BARR VIRUS-TRANSFORMED B LYMPHOCYTES IN VITRO AND IN VIVO: A POTENTIAL APPROACH TO PREVENTION AND TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS", PNAS, vol. 97, 2000, pages 4285 - 4290, XP001093844
MONTINORI, R. ET AL.: "Epithelial tumours of the adult kidney", VIRCHOWS ARCH., vol. 434, 1999, pages 281 - 290, XP055422922
MONTIRONI ET AL.: "Epithehal tumours of the adult kidney", VIRCHOWS ARCH, vol. 434, no. 4, 1999, pages 281 - 290, XP055376578
MOREL D.: "LES INHIBITEURS DE LA MTOR ET LE FTY 720", PRESSE MEDICALE, vol. 30, no. 24, 1 September 2001 (2001-09-01), PARIS, FR, pages 35 - 37, XP009002060, ISSN: 0755-4982
MOREL D: "LES INHIBITEURS DE LA MTOR ET LE FTY 720", PRESSE MEDICALE, PRESSE MEDICALE, PARIS, FR, vol. 30, no. 24, PART 02, 1 September 2001 (2001-09-01), pages 35 - 37, XP009002060, ISSN: 0755-4982 *
MOREL D: "LES INHIBITEURS DE LA MTOR ET LE FTY 720", PRESSE MEDICALE, vol. 30, no. 24, 1 September 2001 (2001-09-01), PARIS, FR, pages 35 - 37, XP009002060
MOREL, D.: "LES INHIBITEURS DE LA MTOR ET LE FTY 720", LA PRESSE MÉDICAL, vol. 30, no. 24, 2001, pages 35 - 37, XP009002060
MOREL, D.: "Les inhibiteurs de la mTOR et le FTY 720", LA PRESSE MÉDICALE, vol. 30, September 2001 (2001-09-01), pages 35 - 37, XP009002060
MOREL: "Les inhibiteurs de la mTOR et le FTY 720.", PRESSE MEDICALE, vol. 30, no. 24, 1 September 2001 (2001-09-01), pages 35 - 37, XP009002060
N. J. VOGELZANG ET AL.: "Kidney cancer", THE LANCET, vol. 352, no. 9141, 1998, pages 1691 - 1696, XP004265807
R. MONTIRONI ET AL.: "Epithehal tumours of the adult kidney", VIRCHOWS ARCH, vol. 434, no. 4, 1999, pages 281 - 290, XP055376578
RAYMOND ET AL.: "# 414 - CCI-779", CLINICAL CANCER RESEARCH, vol. 6, no. Suppl., November 2000 (2000-11-01), pages 4549s, XP055260560
RAYMOND ET AL.: "#414- CCI-779", CLINICAL CANCER RESEARCH, vol. 6, no. Suppl., November 2000 (2000-11-01), pages 4549s, XP055260560
RAYMOND, E. ET AL.: "#414- CCI-779", CLINICAL CANCER RESEARCH, vol. 6, no. Suppl., 2000, pages 4549s, XP055260560
RAYMOND, E. ET AL.: "Abstract 728 CCI-779, a Rapamycin Analog with Antitumor Activity: A Phase I Study Utilizing a Weekly Schedule", PROCEEDINGS ASCO, CLINICAL PHARMACOLOGY, vol. 19, 2000, pages 187a, XP055422938
RAYMOND, E. ET AL.: "CCI-779, an ester analogue of rapamycin that interacts with PTEN/PI3 kinase pathways: A phase I study utilizing a weekly intravenous schedule.", CLIN. CANCER RES., vol. 6, 2000, pages 414s, XP055422919
SCHULER, W. ET AL.: "SDZ RAD, a new rapamycin derivative", TRANSPLANTATION, vol. 64, no. 1, 1997, pages 36 - 42, XP002048032
W. SCHULER ET AL.: "SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo", TRANSPLANTATION, vol. 64, no. 1, 15 July 1997 (1997-07-15), pages 36 - 42, XP002048032
X. LUAN ET AL.: "The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma", ONCOGENE, vol. 15, no. 1, 3 October 2002 (2002-10-03), pages 79 - 86, XP055376607
YU D-S ET AL.: "MONOCLONAL ANTIBODIES AGAINST RENAL TUMORS: THE POTENTIAL APPLICATION IN DISCRIMINATION OF AMBIGUOUS ADENOCARCINOMA OR TRANSITIONAL CELL CARCINOMA OF KIDNEY", JOURNAL OF UROLOGY, vol. 159, no. 1, 1 January 1998 (1998-01-01), BALTIMORE, MD , US, pages 48 - 51, XP009042787, ISSN: 0022-5347
YU D-S ET AL.: "MONOCLONAL ANTIBODIES AGAINST RENAL TUMORS: THE POTENTIAL APPLICATION IN DISCRIMINATION OF AMBIGUOUS ADENOCARCINOMA OR TRANSITIONAL CELL CARONOMA OF KIDNEY'' .", JOURNAL OF UROLOGY., vol. 159, no. 1, 1 January 1998 (1998-01-01), BALTMORE, MD , US, pages 48 - 51, XP009042787, ISSN: 0022-5347
YU D-S ET AL: "MONOCLONAL ANTIBODIES AGAINST RENAL TUMORS: THE POTENTIAL APPLICATION IN DISCRIMINATION OF AMBIGUOUS ADENOCARCINOMA OR TRANSITIONAL CELL CARCINOMA OF KIDNEY", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 159, no. 1, 1 January 1998 (1998-01-01), pages 48 - 51, XP009042787, ISSN: 0022-5347, DOI: 10.1016/S0022-5347(01)64008-4 *
YU, D-S. ET AL.: "MONOCLONAL ANTIBODIES AGAINST RENAL TUMORS: THE POTENTIAL APPLICATION IN DISCRIMINATION OF AMBIGUOUS ADENOCARCINOMA OR TRANSITIONAL CELL CARCINOMA OF KIDNEY", J. UROLOGY, vol. 159, 1998, pages 48 - 51, XP009042787

Also Published As

Publication number Publication date
JP2020143134A (ja) 2020-09-10
RU2445093C2 (ru) 2012-03-20
DK3342411T3 (da) 2019-09-02
JP2007284454A (ja) 2007-11-01
BR0207378A (pt) 2004-06-15
SI3351246T1 (sl) 2019-08-30
WO2002066019A3 (en) 2002-10-24
RU2018121314A3 (OSRAM) 2021-10-06
KR100695846B1 (ko) 2007-03-19
US20120214774A1 (en) 2012-08-23
JP6904640B2 (ja) 2021-07-21
CY1121715T1 (el) 2020-05-29
IL250676B (en) 2018-06-28
PT2269603E (pt) 2015-09-09
CZ309178B6 (cs) 2022-04-20
PL414997A1 (pl) 2016-02-29
LTPA2019521I1 (lt) 2019-12-10
RU2665138C2 (ru) 2018-08-28
US20040147541A1 (en) 2004-07-29
ES2640787T3 (es) 2017-11-06
IL251270A0 (en) 2017-06-29
NO333105B1 (no) 2013-03-04
NO20190290A1 (no) 2003-10-17
PL231418B1 (pl) 2019-02-28
JP6333766B2 (ja) 2018-05-30
RU2322981C2 (ru) 2008-04-27
NO335134B1 (no) 2014-09-22
SK288546B6 (sk) 2018-03-05
DK2269603T3 (en) 2015-08-24
JP2014177469A (ja) 2014-09-25
NO20131547L (no) 2003-10-17
PL415000A1 (pl) 2016-02-29
CY1118316T1 (el) 2017-04-05
CA2994779A1 (en) 2002-08-29
KR100695846B9 (ko) 2021-09-30
LTPA2016035I1 (lt) 2016-12-27
HUP0303271A2 (hu) 2004-01-28
PT3143995T (pt) 2019-01-17
EP3345602B1 (en) 2022-04-06
SK288630B6 (sk) 2019-01-08
SK902019A3 (OSRAM) 2004-03-02
JP6349474B2 (ja) 2018-06-27
DK3143995T3 (en) 2019-01-28
HK1198946A1 (en) 2015-06-19
CZ309247B6 (cs) 2022-06-22
US8410131B2 (en) 2013-04-02
RU2013119705A (ru) 2014-11-10
JP2018100283A (ja) 2018-06-28
CY1121314T1 (el) 2020-05-29
JP2014193901A (ja) 2014-10-09
NO20131546L (no) 2003-10-17
PT3351246T (pt) 2019-06-07
CN1296043C (zh) 2007-01-24
IL259724B (en) 2021-12-01
IL229158A0 (en) 2013-12-31
NO20131544L (no) 2003-10-17
JP6310970B2 (ja) 2018-04-11
CA2438504C (en) 2016-02-16
LU92880I2 (fr) 2016-11-17
ES2728739T3 (es) 2019-10-28
HK1250018B (en) 2020-04-17
JP5873128B2 (ja) 2016-03-01
CA2438504A1 (en) 2002-08-29
JP6349476B2 (ja) 2018-06-27
JP2014208657A (ja) 2014-11-06
HK1197723A1 (en) 2015-02-13
WO2002066019A2 (en) 2002-08-29
LT3351246T (lt) 2019-07-10
CN104083365A (zh) 2014-10-08
NO20130045L (no) 2003-10-17
HUP0303271A3 (en) 2010-09-28
NO336110B1 (no) 2015-05-18
RU2013143306A (ru) 2015-03-27
CN1551767A (zh) 2004-12-01
ES2744377T3 (es) 2020-02-24
CZ2019248A3 (cs) 2004-01-14
US20130244951A1 (en) 2013-09-19
TW200626151A (en) 2006-08-01
JP2018100282A (ja) 2018-06-28
EP3143995B2 (en) 2025-01-15
KR20070102762A (ko) 2007-10-19
NO20033651L (no) 2003-10-17
NO20170803A1 (no) 2003-10-17
ES2921798T3 (es) 2022-08-31
JP2004525899A (ja) 2004-08-26
EP2762140A1 (en) 2014-08-06
EP3342411A1 (en) 2018-07-04
SK288545B6 (sk) 2018-03-05
NO336208B1 (no) 2015-06-15
IL250676A0 (en) 2017-03-30
EP2269603B1 (en) 2015-05-20
CZ200591A3 (cs) 2019-01-23
HK1250019A1 (en) 2018-11-23
US8436010B2 (en) 2013-05-07
JP2018168188A (ja) 2018-11-01
CZ307940B6 (cs) 2019-09-04
EP3351246A1 (en) 2018-07-25
EP3351246B1 (en) 2019-05-22
IL251270B (en) 2018-06-28
EP1363627A2 (en) 2003-11-26
NO343599B1 (no) 2019-04-08
JP2016222705A (ja) 2016-12-28
JP2017081979A (ja) 2017-05-18
US8778962B2 (en) 2014-07-15
NO20131545L (no) 2003-10-17
US20130059877A1 (en) 2013-03-07
IL157425A (en) 2013-10-31
NO340924B1 (no) 2017-07-17
IL229156A0 (en) 2013-12-31
HK1146247A1 (en) 2011-05-27
NO2015010I1 (no) 2015-03-30
US20140105895A1 (en) 2014-04-17
SK288834B6 (sk) 2021-03-10
CA2994779C (en) 2020-08-25
IL220095A0 (en) 2012-07-31
SK10382003A3 (sk) 2004-03-02
CZ2018211A3 (OSRAM) 2004-01-14
AU2002250968C1 (en) 2018-01-04
EP2762140B1 (en) 2017-03-22
CZ20032209A3 (cs) 2004-01-14
EP2783686A1 (en) 2014-10-01
MX368013B (es) 2019-09-13
IL220095A (en) 2017-05-29
PT3345602T (pt) 2022-07-04
SI2269604T1 (sl) 2016-11-30
SI3143995T1 (sl) 2019-02-28
LTPA2019511I1 (lt) 2019-06-25
CN104274442A (zh) 2015-01-14
RU2011138835A (ru) 2013-03-27
ES2629317T3 (es) 2017-08-08
LT2762140T (lt) 2017-06-26
NZ527692A (en) 2005-05-27
EP2269603A1 (en) 2011-01-05
SI3342411T1 (sl) 2019-10-30
EP2783686B1 (en) 2017-06-21
RU2005105664A (ru) 2006-08-10
CY2015044I2 (el) 2017-03-15
EP3143995B1 (en) 2018-12-05
EP2783686A8 (en) 2015-03-04
PL414996A1 (pl) 2016-02-29
SI2762140T1 (sl) 2017-07-31
EP3345602A1 (en) 2018-07-11
CZ303611B6 (cs) 2013-01-09
PT3342411T (pt) 2019-09-19
IL259724A (en) 2018-08-30
RU2018127821A (ru) 2020-01-30
JP5775022B2 (ja) 2015-09-09
IL229160A0 (en) 2013-12-31
SI2269603T1 (sl) 2015-08-31
PT2762140T (pt) 2017-07-04
NO336428B1 (no) 2015-08-17
US20120283285A1 (en) 2012-11-08
CA2860306C (en) 2018-04-17
LUC00122I1 (OSRAM) 2019-06-06
CY1121983T1 (el) 2020-05-29
IL229157A0 (en) 2013-12-31
RU2003127391A (ru) 2005-03-27
CY2019030I1 (el) 2020-05-29
NO336581B1 (no) 2015-09-28
US20130296359A1 (en) 2013-11-07
IL202155A0 (en) 2010-06-16
LT3143995T (lt) 2019-01-25
MX2019010879A (es) 2019-12-16
SK288524B6 (sk) 2018-01-04
RU2006140514A (ru) 2008-05-27
NO20150413L (no) 2003-10-17
EP3342411B1 (en) 2019-08-21
CY2019030I2 (el) 2020-05-29
NO334646B1 (no) 2014-05-05
JP6349475B2 (ja) 2018-06-27
JP2012184238A (ja) 2012-09-27
CN1679559A (zh) 2005-10-12
EP2764865A2 (en) 2014-08-13
NO20150895L (no) 2003-10-17
IL229160B (en) 2018-08-30
TWI334350B (en) 2010-12-11
LU93320I2 (fr) 2017-01-30
US20130287769A1 (en) 2013-10-31
ES2600304T3 (es) 2017-02-08
IL229159A0 (en) 2013-12-31
HK1146245A1 (en) 2011-05-27
NO20161348A1 (no) 2016-08-24
RU2659725C2 (ru) 2018-07-03
KR20040007451A (ko) 2004-01-24
IL229158A (en) 2017-03-30
JP6383814B2 (ja) 2018-08-29
HK1250336B (en) 2020-02-07
JP2018100281A (ja) 2018-06-28
LTPA2020503I1 (lt) 2020-03-10
CZ307637B6 (cs) 2019-01-23
EP3406249A1 (en) 2018-11-28
CY2019043I1 (el) 2020-05-29
IL220096A (en) 2015-10-29
CN104116738A (zh) 2014-10-29
EP3143995A1 (en) 2017-03-22
CY2016047I2 (el) 2017-04-05
LT3342411T (lt) 2019-09-25
NO20120451L (no) 2003-10-17
NO20150831A1 (no) 2015-06-24
LTC2269604I2 (lt) 2020-01-27
PL409579A1 (pl) 2015-03-02
MXPA03007418A (es) 2003-11-18
DK2762140T3 (en) 2017-07-10
CA2860306A1 (en) 2002-08-29
AU2002250968B2 (en) 2006-01-12
RU2018121314A (ru) 2019-12-10
RU2483727C1 (ru) 2013-06-10
PT2269604T (pt) 2016-11-04
CY2016047I1 (el) 2017-04-05
JP5879391B2 (ja) 2016-03-08
NO339240B1 (no) 2016-11-21
RU2325906C2 (ru) 2008-06-10
LT2269604T (lt) 2016-11-10
CZ2010473A3 (OSRAM) 2004-01-14
US8877771B2 (en) 2014-11-04
EP2764865A3 (en) 2014-10-01
LUC00122I2 (OSRAM) 2019-12-24
PL363918A1 (pl) 2004-11-29
EP2269604A1 (en) 2011-01-05
IL229156A (en) 2017-02-28
ES2705016T3 (es) 2019-03-21
NO20033651D0 (no) 2003-08-18
DK2269604T3 (en) 2016-11-14
CY1119029T1 (el) 2018-01-10
KR20050095906A (ko) 2005-10-04
EP3351246B8 (en) 2019-09-18
CY2015044I1 (el) 2017-03-15
JP2015145411A (ja) 2015-08-13
CY1116616T1 (el) 2017-03-15
IL157425A0 (en) 2004-03-28
US20130253000A1 (en) 2013-09-26
DK3351246T3 (da) 2019-06-03
NO340553B1 (no) 2017-05-08
US20160303092A1 (en) 2016-10-20
CY2020005I1 (el) 2020-05-29
ES2543383T3 (es) 2015-08-18
IL202155A (en) 2013-04-30
IL220096A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
EP2269604B1 (en) Treatment of solid kidney tumours with a rapamycin derivative
US20250041298A1 (en) Cdk4 inhibitor for the treatment of cancer
HK1146245B (en) Treatment of solid kidney tumours with a rapamycin derivative
HK1232469B (en) Rapamycin derivative for the treatment of lung cancer
HK1197723B (en) Treatment of solid brain tumours with a rapamycin derivative
AU2019222912B2 (en) Cancer treatment
HK1198946B (en) Combination of a rapamycin derivative and letrozole for treating breast cancer
HK1146247B (en) Treatment of breast tumors with a rapamycin derivative in combination with exemestane
AU2014202334B2 (en) Cancer treatment
AU2011226835B2 (en) Cancer treatment
AU2007201060B2 (en) Cancer treatment
SK288719B6 (sk) 40-O-(2-hydroxyetyl)-rapamycín na použitie ako jediná účinná zložka pri liečení pevného nádoru

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1363627

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: LT LV RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1146245

Country of ref document: HK

17P Request for examination filed

Effective date: 20110705

17Q First examination report despatched

Effective date: 20140121

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 60248225

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031436000

Ipc: A61K0045060000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7068 20060101ALI20151214BHEP

Ipc: A61K 31/436 20060101ALI20151214BHEP

Ipc: A61K 31/555 20060101ALI20151214BHEP

Ipc: A61K 31/5685 20060101ALI20151214BHEP

Ipc: A61P 35/00 20060101ALI20151214BHEP

Ipc: A61K 31/502 20060101ALI20151214BHEP

Ipc: A61K 31/475 20060101ALI20151214BHEP

Ipc: A61K 31/704 20060101ALI20151214BHEP

Ipc: A61K 45/06 20060101AFI20151214BHEP

Ipc: A61K 31/337 20060101ALI20151214BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160125

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS AG

AC Divisional application: reference to earlier application

Ref document number: 1363627

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: LT LV RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60248225

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2269604

Country of ref document: PT

Date of ref document: 20161104

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20161025

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20161110

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: FI

Ref legal event code: SPCF

Spc suppl protection certif: C20160048

REG Reference to a national code

Ref country code: IT

Ref legal event code: SPCF

Ref document number: 502016000108057

Country of ref document: IT

Free format text: PRODUCT NAME: EVEROLIMUS O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(AFINITOR); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/09/538/001-006, 20090805

Spc suppl protection certif: 132016000127697

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: EVEROLIMUS OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: 16C0044

Filing date: 20161219

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCF

Free format text: PRODUCT NAME: EVEROLIMUS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/09/538/001-006 (C(2009)6251) 20090805

Spc suppl protection certif: 300849

Filing date: 20161215

Expiry date: 20220217

Extension date: 20240804

REG Reference to a national code

Ref country code: LT

Ref legal event code: SPCF

Free format text: PRODUCT NAME: EVEROLIMUZAS; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090803

Spc suppl protection certif: PA2016035

Filing date: 20161128

Expiry date: 20220218

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: EVEROLIMUS; REG. NO/DATE: EU/1/09/538/ 20090805

Spc suppl protection certif: 1690057-3

Ref country code: DE

Ref legal event code: R065

Ref document number: 60248225

Country of ref document: DE

Free format text: PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090803

Spc suppl protection certif: 122016000094

Filing date: 20161202

Expiry date: 20220219

Extension date: 20240805

REG Reference to a national code

Ref country code: IE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: EVEROLIMUS OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090803

Spc suppl protection certif: 2016/055

Filing date: 20161214

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFF

Free format text: PRODUCT NAME: EVEROLIMUS ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: CA 2016 00060

Filing date: 20161212

Expiry date: 20220218

Extension date: 20240805

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: LU

Ref legal event code: CCP

Free format text: PRODUCT NAME: TRAITEMENT DE TUMEURS SOLIDES RENALES AVEC UN DERIVE DE LA RAPAMYCINE

Spc suppl protection certif: 93320

Extension date: 20240805

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCF

Free format text: PRODUCT NAME: EVEROLIMUS (40-O-(2-HYDROXYETHYL)-RAPAMYCIN); REGISTRATION NO/DATE: SWISSMEDIC 59174 17.11.2009

Spc suppl protection certif: C02269604/01

Filing date: 20170120

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFF

Free format text: PRODUCT NAME: EVEROLIMUS OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/09/538/001 20090805; UK EU/1/09/538/002 20090805; UK EU/1/09/538/003 20090805; UK EU/1/09/538/004 20090805; UK EU/1/09/538/005 20090805; UK EU/1/09/538/006 20090805; UK (C(2009)6251) 20090805

Spc suppl protection certif: SPC/GB17/003

Filing date: 20161219

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2600304

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170208

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20160402618

Country of ref document: GR

Effective date: 20170130

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCF

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; NAT. REGISTRATION NO/DATE: (C(2009)6251) 20090805; FIRST REGISTRATION: EU/1/09/538/001-006 20090803

Spc suppl protection certif: 62/2016

Filing date: 20161214

Effective date: 20170315

REG Reference to a national code

Ref country code: IT

Ref legal event code: SPCG

Ref document number: 502016000108057

Country of ref document: IT

Free format text: PRODUCT NAME: EVEROLIMUS O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(AFINITOR); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/09/538/001-006, 20090805

Spc suppl protection certif: 132016000127697

Extension date: 20240803

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1146245

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 60248225

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: SYNTHON BIOPHARMACEUTICALS B.V.

Effective date: 20170424

26 Opposition filed

Opponent name: STADA ARZNEIMITTEL AG

Effective date: 20170427

Opponent name: TEVA PHARMACEUTICAL INDUSTRIES LTD

Effective date: 20170427

Opponent name: KRKA, D.D., NOVO MESTO

Effective date: 20170426

Opponent name: GENERICS (UK) LTD

Effective date: 20170427

Opponent name: FRESENIUS KABI DEUTSCHLAND GMBH

Effective date: 20170426

Opponent name: WITTKOPP, ALEXANDER

Effective date: 20170427

Opponent name: INTAS PHARMACEUTICALS LTD.

Effective date: 20170427

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

REG Reference to a national code

Ref country code: LU

Ref legal event code: SPCG

Free format text: PRODUCT NAME: EVEROLIMUS OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/09/538-001-006 - AFINITOR - EVEROLIMUS

Spc suppl protection certif: 93320

Filing date: 20161123

Expiry date: 20220218

Extension date: 20240805

Effective date: 20170130

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCG

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: 62/2016

Filing date: 20161214

Expiry date: 20220218

Extension date: 20240805

Effective date: 20171115

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: DE

Ref legal event code: R067

Ref document number: 60248225

Country of ref document: DE

Free format text: PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090803

Spc suppl protection certif: 122016000094

Filing date: 20161202

Expiry date: 20220219

Extension date: 20240805

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCR

Spc suppl protection certif: 1690057-3

REG Reference to a national code

Ref country code: DE

Ref legal event code: R069

Ref document number: 60248225

Country of ref document: DE

Free format text: PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090803

Spc suppl protection certif: 122016000094

Filing date: 20161202

Expiry date: 20220219

Extension date: 20240805

REG Reference to a national code

Ref country code: FR

Ref legal event code: SPCU

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG, CH

Free format text: PRODUCT NAME: EVEROLIMUS OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: 16C0044

Filing date: 20161219

Ref country code: FR

Ref legal event code: SPCU

Owner name: NOVARTIS PHARMA AG, CH

Free format text: PRODUCT NAME: EVEROLIMUS OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: 16C0044

Filing date: 20161219

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20180712 AND 20180718

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 60248225

Country of ref document: DE

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG, CH

Free format text: FORMER OWNER: NOVARTIS AG, 4056 BASEL, CH

Ref country code: DE

Ref legal event code: R081

Ref document number: 60248225

Country of ref document: DE

Owner name: NOVARTIS PHARMA AG, CH

Free format text: FORMER OWNER: NOVARTIS AG, 4056 BASEL, CH

REG Reference to a national code

Ref country code: FR

Ref legal event code: TQ

Owner name: NOVARTIS PHARMA AG, CH

Effective date: 20180709

Ref country code: FR

Ref legal event code: TQ

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG, CH

Effective date: 20180709

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCM

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG, CH

Free format text: FORMER OWNER: NOVARTIS PHARMA AG, CH

Spc suppl protection certif: C02269604/01

Ref country code: CH

Ref legal event code: PUE

Owner name: NOVARTIS PHARMA AG, CH

Free format text: FORMER OWNER: NOVARTIS AG, CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Effective date: 20180917

Ref country code: ES

Ref legal event code: PC2A

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG

Effective date: 20180917

REG Reference to a national code

Ref country code: BE

Ref legal event code: SPCT

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION

Spc suppl protection certif: 2016C/075

Effective date: 20180725

Ref country code: BE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: EVEROLIMUS OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: 2016C/075

Filing date: 20161214

Expiry date: 20220218

Ref country code: BE

Ref legal event code: PD

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION; FORMER OWNER NAME: NOVARTIS AG

Effective date: 20180725

Ref country code: BE

Ref legal event code: FP

Effective date: 20161020

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCT

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT

Spc suppl protection certif: 300849

Effective date: 20180926

Ref country code: NL

Ref legal event code: PD

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: NOVARTIS AG

Effective date: 20180926

R26 Opposition filed (corrected)

Opponent name: GENERICS (UK) LTD

Effective date: 20170427

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: KRKA, D.D., NOVO MESTO

Effective date: 20170426

REG Reference to a national code

Ref country code: LU

Ref legal event code: SPCC

Spc suppl protection certif: 93320

Name of requester: N.V. NOVARTIS PHARMA S.A.

Effective date: 20190313

Ref country code: LU

Ref legal event code: SPCT

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG; CH

Spc suppl protection certif: 93320

Effective date: 20190313

Ref country code: LU

Ref legal event code: QB

Name of requester: N.V. NOVARTIS PHARMA S.A.

Effective date: 20190327

Ref country code: LU

Ref legal event code: PD

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG; CH

Free format text: FORMER OWNER: NOVARTIS AG

Effective date: 20190313

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCT

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Owner name: NOVARTIS PHARMA AG, CH

Free format text: PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: 62/2016

Filing date: 20161214

Expiry date: 20220218

Extension date: 20240805

Effective date: 20190320

Ref country code: AT

Ref legal event code: SPCT

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG, CH

Free format text: PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: 62/2016

Filing date: 20161214

Expiry date: 20220218

Extension date: 20240805

Effective date: 20190320

Ref country code: AT

Ref legal event code: PC

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG, CH

Effective date: 20190320

Ref country code: AT

Ref legal event code: PC

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Owner name: NOVARTIS PHARMA AG, CH

Effective date: 20190320

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCC

Free format text: DETAILS LICENCE: LICENCE, NEW LICENCE REGISTRATION

Spc suppl protection certif: 300849

Name of requester: NOVARTIS PHARMA B.V.

Effective date: 20180926

Ref country code: NL

Ref legal event code: QB

Free format text: DETAILS LICENCE OR PLEDGE: LICENCE, NEW LICENCE REGISTRATION

Name of requester: NOVARTIS PHARMA B.V.

Effective date: 20190510

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20190718 AND 20190724

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG; CH

Effective date: 20190724

PLCK Communication despatched that opposition was rejected

Free format text: ORIGINAL CODE: EPIDOSNREJ1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

REG Reference to a national code

Ref country code: BE

Ref legal event code: SPCC

Free format text: DETAILS LICENCE: LICENCE, ENREGISTREMENT D'UNE NOUVELLE LICENCE

Spc suppl protection certif: 2016C/075

Name of requester: N.V. NOVARTIS PHARMA S.A.

Effective date: 20180725

Ref country code: BE

Ref legal event code: QB

Free format text: DETAILS LICENCE: LICENCE, ENREGISTREMENT D'UNE NOUVELLE LICENCE

Name of requester: N.V. NOVARTIS PHARMA S.A.

Effective date: 20190626

REG Reference to a national code

Ref country code: ES

Ref legal event code: SPCD

Free format text: PRODUCT NAME: EVEROLIMUS O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/09/538/001-006; DATE OF AUTHORISATION: 20090803; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/09/538/001-006; DATE OF FIRST AUTHORISATION IN EEA: 20090803

Spc suppl protection certif: C201630076

Effective date: 20191010

REG Reference to a national code

Ref country code: SI

Ref legal event code: LIQB

Effective date: 20190829

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

REG Reference to a national code

Ref country code: LT

Ref legal event code: SPCG

Free format text: PRODUCT NAME: EVEROLIMUZAS; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090803

Spc suppl protection certif: PA2016035,C2269604

Filing date: 20161128

Expiry date: 20220218

Extension date: 20240805

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

REG Reference to a national code

Ref country code: ES

Ref legal event code: GD2A

Effective date: 20200518

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 60248225

Country of ref document: DE

Owner name: NOVARTIS PHARMA AG, CH

Free format text: FORMER OWNERS: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG, BASEL, CH; NOVARTIS PHARMA AG, BASEL, CH

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFUS

Owner name: NOVARTIS PHARMA AG, CH

Free format text: FORMER OWNER: NOVARTIS PHARMA AG, CH

REG Reference to a national code

Ref country code: LU

Ref legal event code: SPCT

Owner name: NOVARTIS PHARMA AG; CH

Spc suppl protection certif: 93320

Effective date: 20200610

Ref country code: LU

Ref legal event code: PD

Owner name: NOVARTIS PHARMA AG; CH

Free format text: FORMER OWNER: NOVARTIS AG

Effective date: 20200610

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160727

REG Reference to a national code

Ref country code: FR

Ref legal event code: SPCT

Owner name: NOVARTIS PHARMA AG, CH

Free format text: PRODUCT NAME: EVEROLIMUS OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: 16C0044

Filing date: 20161219

REG Reference to a national code

Ref country code: FR

Ref legal event code: CX

Free format text: PRODUCT NAME: EVEROLIMUS OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: 16C0044

Filing date: 20161219

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20200813 AND 20200819

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCT

Owner name: NOVARTIS PHARMA AG; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE

Spc suppl protection certif: 300849

Effective date: 20200909

Ref country code: NL

Ref legal event code: PD

Owner name: NOVARTIS PHARMA AG; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE; FORMER OWNER NAME: NOVARTIS PHARMA AG

Effective date: 20200909

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFW

Free format text: PRODUCT NAME: EVEROLIMUS ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: CA 2016 00060

Filing date: 20161212

Expiry date: 20220218

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: NOVARTIS PHARMA AG; CH

Effective date: 20200824

REG Reference to a national code

Ref country code: FI

Ref legal event code: SPCL

Spc suppl protection certif: C20160048

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCT

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Owner name: NOVARTIS PHARMA AG, CH

Free format text: PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: 62/2016

Filing date: 20161214

Expiry date: 20220218

Extension date: 20240805

Effective date: 20200818

Ref country code: AT

Ref legal event code: PC

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Owner name: NOVARTIS PHARMA AG, CH

Effective date: 20200818

REG Reference to a national code

Ref country code: IE

Ref legal event code: SPCW

Free format text: PRODUCT NAME: EVEROLIMUS OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090803

Spc suppl protection certif: 2016/055

Filing date: 20161214

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCG

Free format text: PRODUCT NAME: EVEROLIMUS (40-O-(2-HYDROXYETHYL)-RAPAMYCIN); REGISTRATION NO/DATE: SWISSMEDIC AUTHORISATION 59174 17.11.2009

Spc suppl protection certif: C02269604/01

Filing date: 20170120

Extension date: 20241116

REG Reference to a national code

Ref country code: FI

Ref legal event code: PCE

Owner name: NOVARTIS PHARMA AG

REG Reference to a national code

Ref country code: LT

Ref legal event code: SPCW

Free format text: PRODUCT NAME: EVEROLIMUZAS; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090803

Spc suppl protection certif: PA2016035,C2269604

Filing date: 20161128

Expiry date: 20220218

Extension date: 20240805

Effective date: 20201125

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: NOVARTIS PHARMA AG

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFW

Free format text: PRODUCT NAME: EVEROLIMUS OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/09/538/001 20090805; UK EU/1/09/538/002 20090805; UK EU/1/09/538/003 20090805; UK EU/1/09/538/004 20090805; UK EU/1/09/538/005 20090805; UK EU/1/09/538/006 20090805; UK (C(2009)6251) 20090805

Spc suppl protection certif: SPC/GB17/003

Filing date: 20161219

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: NOVARTIS PHARMA AG; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), FUSION; FORMER OWNER NAME: NOVARTIS AG

Effective date: 20200605

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCW

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090805

Spc suppl protection certif: 62/2016

Filing date: 20161214

Expiry date: 20220218

Extension date: 20240805

Effective date: 20220218

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: NOVARTIS PHARMA AG; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE; FORMER OWNER NAME: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG

Effective date: 20210127

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20210126

Year of fee payment: 20

Ref country code: CH

Payment date: 20210217

Year of fee payment: 20

Ref country code: CY

Payment date: 20210122

Year of fee payment: 20

Ref country code: FI

Payment date: 20210209

Year of fee payment: 20

Ref country code: NL

Payment date: 20210212

Year of fee payment: 20

Ref country code: MC

Payment date: 20210126

Year of fee payment: 20

Ref country code: LU

Payment date: 20210210

Year of fee payment: 20

Ref country code: GR

Payment date: 20210126

Year of fee payment: 20

Ref country code: IE

Payment date: 20210209

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20210210

Year of fee payment: 20

Ref country code: SE

Payment date: 20210210

Year of fee payment: 20

Ref country code: TR

Payment date: 20210216

Year of fee payment: 20

Ref country code: BE

Payment date: 20210125

Year of fee payment: 20

Ref country code: AT

Payment date: 20210125

Year of fee payment: 20

Ref country code: DE

Payment date: 20210202

Year of fee payment: 20

Ref country code: GB

Payment date: 20210210

Year of fee payment: 20

Ref country code: ES

Payment date: 20210305

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R103

Ref document number: 60248225

Country of ref document: DE

Ref country code: DE

Ref legal event code: R064

Ref document number: 60248225

Country of ref document: DE

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20210126

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

REG Reference to a national code

Ref country code: FI

Ref legal event code: MGE

27W Patent revoked

Effective date: 20210729

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20210729

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM9A

Effective date: 20220218

REG Reference to a national code

Ref country code: GR

Ref legal event code: NF

Ref document number: 20160402618

Country of ref document: GR

Effective date: 20211111

R26 Opposition filed (corrected)

Opponent name: TEVA PHARMACEUTICAL INDUSTRIES LTD

Effective date: 20170427

REG Reference to a national code

Ref country code: AT

Ref legal event code: MA03

Ref document number: 815260

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210729

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCL

Spc suppl protection certif: C02269604/01

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230511

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20250822

Year of fee payment: 20